Regeneron Pharmaceuticals, Inc [REGN] stock is trading at $570.59, up 0.50%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The REGN shares have gain 6.04% over the last week, with a monthly amount glided 10.03%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Regeneron Pharmaceuticals, Inc [NASDAQ: REGN] stock has seen the most recent analyst activity on June 30, 2025, when Argus downgraded its rating to a Hold. Previously, Wells Fargo downgraded its rating to Equal Weight on May 30, 2025, and kept the price target unchanged to $580. On May 30, 2025, downgrade downgraded it’s rating to Sector Perform but maintained its price target of $662 on the stock. Citigroup upgraded its rating to a Buy but stick to its price target of $700 on May 14, 2025. Leerink Partners upgraded its rating to Outperform for this stock on February 05, 2025, and upped its price target to $834. In a note dated January 16, 2025, UBS downgraded an Neutral rating on this stock and revised its target price from $1130 to $738.
Regeneron Pharmaceuticals, Inc [REGN] stock has fluctuated between $476.49 and $1211.20 over the past year. Currently, Wall Street analysts expect the stock to reach $757.2 within the next 12 months. Regeneron Pharmaceuticals, Inc [NASDAQ: REGN] shares were valued at $570.59 at the most recent close of the market. An investor can expect a potential return of 32.7% based on the average REGN price forecast.
Analyzing the REGN fundamentals
Regeneron Pharmaceuticals, Inc [NASDAQ:REGN] reported sales of 14.09B for the trailing twelve months, which represents a drop of -3.70%. Gross Profit Margin for this corporation currently stands at 0.85% with Operating Profit Margin at 0.27%, Pretax Profit Margin comes in at 0.35%, and Net Profit Margin reading is 0.32%. To continue investigating profitability, this company’s Return on Assets is posted at 0.12, Equity is 0.15 and Total Capital is 0.11. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 563.35 points at the first support level, and at 556.11 for the second support level. However, for the 1st resistance point, the stock is sitting at 576.48, and for the 2nd resistance point, it is at 582.37.
Ratios To Look Out For
For context, Regeneron Pharmaceuticals, Inc’s Current Ratio is 4.93. Also, the Quick Ratio is 4.03, while the Cash Ratio stands at 0.87. Considering the valuation of this stock, the price to sales ratio is 4.37, the price to book ratio is 2.10 and price to earnings (TTM) ratio is 14.52.
Transactions by insiders
Recent insider trading involved McCourt Marion, EVP Commercial, that happened on Nov 01 ’24 when 1000.0 shares were sold. Officer, MARION E MCCOURT completed a deal on Nov 01 ’24 to buy 1000.0 shares. Meanwhile, Director RYAN ARTHUR F sold 100.0 shares on Oct 01 ’24.
